ESMO 2022 | Therapeutic implications of PSMA

Neil Bander, MD, Weill Cornell Medical College, New York City, NY, discusses two therapeutic challenges regarding PSMA biology for patients with prostate cancer. One challenge is controlling the degree of expression of PSMA in the tumor by using anti-androgen therapies, which are able to upregulate the level of PSMA expression on the tumor surface. The second challenge is the delivery of PSMA-targeting drugs and the internalisation and retention of these agents by the tumor cell. Dr Bander discusses the combination of small molecule ligands and antibodies as a potential solution. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.